Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

OBJECTIVE: Sulfonylureas are first-line treatment of hepatocyte nuclear factor 1-α (HNF1A) diabetes (maturity-onset diabetes of the young type 3), but many patients do not achieve optimal glycemic control without episodes of hypoglycemia. We investigated the combination of the sulfonylurea glimepiri...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Alexander S., Hædersdal, Sofie, Støy, Julie, Storgaard, Heidi, Kampmann, Ulla, Forman, Julie L., Seghieri, Marta, Holst, Jens J., Hansen, Torben, Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440905/
https://www.ncbi.nlm.nih.gov/pubmed/32661107
http://dx.doi.org/10.2337/dc20-0408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440905/
https://www.ncbi.nlm.nih.gov/pubmed/32661107
http://dx.doi.org/10.2337/dc20-0408

Ejemplares similares